Cubist Pharmaceuticals CEO Michael Bonney: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec discusses the development and eventual approval of the first-in-class antibiotic Cubicin.
You may also be interested in...
Cubist Pharmaceuticals CEO Michael Bonney: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses the regulatory climate for anti-infectives and Cubist’s development plans following the successful launch of Cubicin.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.